Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early front-loaded eptifibatide in high-risk non-ST-segment elevation acute coronary syndrome
2004-000120-32Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eptifibatide in acute coronary syndrome (ACS) (2 arms), sponsored by Merck & Co. Primary endpoint: Composite ischemic endpoint within 96 hours. Started Oct 2004; status: completed.
02
Drugs
eptifibatide
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2004-000120-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000120-32.